These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 25901432)

  • 1. Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
    Vannucchi AM
    N Engl J Med; 2015 Apr; 372(17):1670-1. PubMed ID: 25901432
    [No Abstract]   [Full Text] [Related]  

  • 2. Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
    Hasselbalch HC; Bjørn ME
    N Engl J Med; 2015 Apr; 372(17):1670. PubMed ID: 25901433
    [No Abstract]   [Full Text] [Related]  

  • 3. Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
    Vannucchi AM; Kiladjian JJ; Griesshammer M; Masszi T; Durrant S; Passamonti F; Harrison CN; Pane F; Zachee P; Mesa R; He S; Jones MM; Garrett W; Li J; Pirron U; Habr D; Verstovsek S
    N Engl J Med; 2015 Jan; 372(5):426-35. PubMed ID: 25629741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies.
    Kiladjian JJ; Guglielmelli P; Griesshammer M; Saydam G; Masszi T; Durrant S; Passamonti F; Jones M; Zhen H; Li J; Gadbaw B; Perez Ronco J; Khan M; Verstovsek S
    Ann Hematol; 2018 Apr; 97(4):617-627. PubMed ID: 29396713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ruxolitinib: evolution or revolution in treatment of patients with polycythemia vera?
    Beauverd Y; McLornan DP; Radia DH; Harrison CN
    Future Oncol; 2016 Mar; 12(6):739-49. PubMed ID: 26846873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remission of recalcitrant dermatomyositis treated with ruxolitinib.
    Hornung T; Janzen V; Heidgen FJ; Wolf D; Bieber T; Wenzel J
    N Engl J Med; 2014 Dec; 371(26):2537-8. PubMed ID: 25539124
    [No Abstract]   [Full Text] [Related]  

  • 7. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.
    Verstovsek S; Vannucchi AM; Griesshammer M; Masszi T; Durrant S; Passamonti F; Harrison CN; Pane F; Zachee P; Kirito K; Besses C; Hino M; Moiraghi B; Miller CB; Cazzola M; Rosti V; Blau I; Mesa R; Jones MM; Zhen H; Li J; Francillard N; Habr D; Kiladjian JJ
    Haematologica; 2016 Jul; 101(7):821-9. PubMed ID: 27102499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevation of the Hepatitis B Virus DNA during the Treatment of Polycythemia Vera with the JAK Kinase Inhibitor Ruxolitinib.
    Kirito K; Sakamoto M; Enomoto N
    Intern Med; 2016; 55(10):1341-4. PubMed ID: 27181544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ruxolitinib for the treatment of patients with polycythemia vera.
    Kiladjian JJ; Winton EF; Talpaz M; Verstovsek S
    Expert Rev Hematol; 2015 Aug; 8(4):391-401. PubMed ID: 25980454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic leg ulceration associated with polycythemia vera responding to ruxolitinib (Jakafi(®)).
    Shanmugam VK; McNish S; Shara N; Hubley KJ; Kallakury B; Dunning DM; Attinger CE; Steinberg JS
    J Foot Ankle Surg; 2013; 52(6):781-5. PubMed ID: 23953278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloproliferative neoplasm in a thalassaemic patient: response to treatment with a JAK inhibitor.
    Martinez-Lopez J; Jimenez A; Sanchez-Calero J; Monteagudo D; Urbanowicz M; Cañamares-Orbis I; Cortijo-Cascajares S; Ayala R
    Ann Hematol; 2015 Jul; 94(7):1237-9. PubMed ID: 25791242
    [No Abstract]   [Full Text] [Related]  

  • 12. Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide.
    Harrison CN; Griesshammer M; Miller C; Masszi T; Passamonti F; Zachee P; Durrant S; Pane F; Guglielmelli P; Verstovsek S; Jones MM; Hunter DS; Sun W; Li J; Khan M; Habr D; Kiladjian JJ
    Br J Haematol; 2018 Jul; 182(2):279-284. PubMed ID: 29984424
    [No Abstract]   [Full Text] [Related]  

  • 13. New therapies for polycythemia vera.
    Verstovsek S
    Clin Adv Hematol Oncol; 2015 Jun; 13(6):356-8. PubMed ID: 26352890
    [No Abstract]   [Full Text] [Related]  

  • 14. Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera.
    Coltoff A; Mesa R; Gotlib J; Shulman J; Rampal RK; Siwoski O; Yacoub A; Moliterno A; Yang A; Braunstein E; Gerds AT; Hobbs GS; Winton EF; Goel S; Wadleigh M; Tremblay D; Moshier E; Mascarenhas J
    Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):697-703.e1. PubMed ID: 32624445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available.
    Foltz L; Pica GM; Zerazhi H; Van Droogenbroeck J; Visanica S; Báez de la Fuente E; Leber B; de Almeida AM; Ranta D; Kiladjian JJ; Chrit L; Kandra A; Morando J; Devos T
    Leuk Lymphoma; 2019 Dec; 60(14):3493-3502. PubMed ID: 31359808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hematologic Malignancies/Pediatric Malignancies. I. Ruxolitinib Therapy for Myelofibrosis and Polycythemia Vera].
    Komatsu N
    Gan To Kagaku Ryoho; 2016 May; 43(5):530-4. PubMed ID: 27344680
    [No Abstract]   [Full Text] [Related]  

  • 17. Evidence for Janus kinase (JAK) inhibitors for the prevention of major morbid events in patients with myeloproliferative neoplasms (MPNs).
    Pemmaraju N; Mesa R
    Hematology Am Soc Hematol Educ Program; 2015; 2015():649-51. PubMed ID: 26637784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy.
    Verstovsek S; Harrison CN; Kiladjian JJ; Miller C; Naim AB; Paranagama DC; Habr D; Vannucchi AM
    Leuk Res; 2017 May; 56():52-59. PubMed ID: 28193568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polycythaemia vera, ruxolitinib, and hydroxyurea: where do we go now?
    Spivak JL
    Lancet Haematol; 2020 Mar; 7(3):e184-e185. PubMed ID: 31982040
    [No Abstract]   [Full Text] [Related]  

  • 20. ruxolitinib (JAKAVI°) and polycythaemia vera Inconclusive evaluation.
    Prescrire Int; 2016 Oct; 25(175):229-231. PubMed ID: 30645821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.